Imaging of Apoptosis and Hypoxia

  • David J. Yang
  • E. Edmund Kim

Abstract

Tumor cells are more sensitive to conventional irradiation in the presence of oxygen than in its absence; even a small percentage of hypoxic cells within a tumor could limit the response to radiation [1–4]. Hypoxic radioresistance has been demonstrated in many animal tumors but only in a few tumor types in humans [5–9]. The occurrence of hypoxia in human tumors has, in most cases, been inferred from histological findings and from animal tumor studies. In vivo demonstration of hypoxia has required tissue measurements with oxygen electrodes, and the invasiveness of these techniques has limited their clinical application. Additionally, this technique can only be used on accessible tumors such as head and neck tumor. Many attempts to increase the radiosensitivity of tumors by administration of chemical radiosensitizers have not been successful [10–14].

Keywords

Positron Emission Tomography Radiat Oncol Biol Phys Tumor Hypoxia Post Administration Image Apoptosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hall EJ. The oxygen effect and reoxygenation. In: Hall EJ, ed. Radiobiology for the Radiobiologist. Philadelphia: Lippincott, 1988:137–160.Google Scholar
  2. 2.
    Bush RS, Jenkins RDT, Allt WEC, et al. Definite evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 1978;37:302–306.Google Scholar
  3. 3.
    Hohman WF, Palcic B, Skarsgard LD. The effect of nitroimidazole and nitroxyl radiosensitizers on the post-irradiation synthesis of DNA. Int J Radiat Biol Relat Stud Phys Chem Med 1976; 30:247–261.PubMedCrossRefGoogle Scholar
  4. 4.
    Gray LH, Conger AD, Elbert M. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638–648.PubMedCrossRefGoogle Scholar
  5. 5.
    Dische S. A review of hypoxic-cell radiosensitization. Int J Radiat Oncol Biol Phys 1991; 20:147–152.PubMedCrossRefGoogle Scholar
  6. 6.
    Gray LH, Conger AD, Ebert M, et al. The concentration of oxygen dissolved in tissue at the time of irradiation as a factor in radiotherapy. Br J Cancer 1953;26:638–642.Google Scholar
  7. 7.
    Dische S, Gray AJ, Zanelli GD. Clinical testing of the radiosensitizer Ro-07–0582. II. Radiosensitization of normal and hypoxic skin. Clin Radiol 1976;27:159–166.PubMedCrossRefGoogle Scholar
  8. 8.
    Gatenby RA, Kessler HB, Rosenblum JS, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988;14:831–838.PubMedCrossRefGoogle Scholar
  9. 9.
    Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41:31–39.PubMedGoogle Scholar
  10. 10.
    Martin FD, Porter EA, Fischer JJ, et al. Effect of a perfluorochemical emulsion on the radiation response of BA1112 rhabdomyosarcomas. Radiat Res 1987;112:45–53.PubMedCrossRefGoogle Scholar
  11. 11.
    Martin DF, Porter EA, Rockwell S, et al. Enhancement of tumor radiation response by the combination of a perfluorochemical emulsion and hyperbaric oxygen. Int J Radiat Oncol Biol Phys 1987;13:747–751.PubMedCrossRefGoogle Scholar
  12. 12.
    Peters LJ, Withers HR, Thames HD, et al. Keynote address-The problem: tumor radioresistance in clinical radiotherapy. Int J Radiat Oncol Biol Phys 1982;8:101–108.PubMedCrossRefGoogle Scholar
  13. 13.
    Phillips TL. Chemical modification of radiation effects. Cancer (Phila) 1977;39:987–998.CrossRefGoogle Scholar
  14. 14.
    Mohindra JK, Rauth AM. Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Res 1976;36:930–936.PubMedGoogle Scholar
  15. 15.
    Koh W-J, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [18F]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992;22:199–212.PubMedCrossRefGoogle Scholar
  16. 16.
    Valk PET, Mathis CA, Prados MD, et al. Hypoxia in human gliomas: demonstration by PET with [18F]fluoromisonidazole. J Nucl Med 1992;33: 2133–2137.PubMedGoogle Scholar
  17. 17.
    Martin GV, Caldwell JH, Rasey JS, et al. Enhanced binding of the hypoxic cell marker [18F]fluoromisonidazole in ischemic myocardium. J Nucl Med 1989;30:194–201.PubMedGoogle Scholar
  18. 18.
    Rasey JS, Koh WJ, Grieson JR, et al. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989;17:985–991.PubMedCrossRefGoogle Scholar
  19. 19.
    Rasey JS, Nelson NJ, Chin L, et al. Characterization of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res 1990;122:301–308.PubMedCrossRefGoogle Scholar
  20. 20.
    Yang DJ, Wallace S, Cherif A, et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995;194:795–800.PubMedGoogle Scholar
  21. 21.
    Cherif A, Wallace S, Yang DJ, et al. Development of new markers for hypoxic cells: [131I] iodomisonidazole and [131I] iodoerythronitroimidazole. J Drug Targeting 1996;4:31–39.CrossRefGoogle Scholar
  22. 22.
    Johnson G, Nguyen KN, Lui Z, et al. HL91 Technetium-99m: a potential new marker of myocardial viability assessed by nuclear imaging early after reperfusion. J Nucl Cardiol 1998; 5:285–294.PubMedCrossRefGoogle Scholar
  23. 23.
    Fukuchi K, Kusuoka H, Yutani K, et al. Assessment of reperfused myocardium using new hypoxia avid imaging agent 99mTc-HL91. J Nucl Med 1996;37:94P.Google Scholar
  24. 24.
    Melo T, Duncan J, Ballinger JR, et al. BMS 194796, a second generation 99mTc labeled 2-nitroimidazole for imaging hypoxia in tumors. J Nucl Med 1998;39:219P.Google Scholar
  25. 25.
    Zhang X, Melo T, Ballinger JR, et al. Evaluation of 99mTc-butyleneamino oxime (BnAO), a non-nitroaromatic agent for imaging hypoxia in tumors. J Nucl Med 1998;39:216P.Google Scholar
  26. 26.
    Foster JL, Conroy PJ, Searle AJ, et al. Metronidazole (Flagyl): characterization as a cytotoxic drug specific for hypoxic tumour cells. Br J Cancer 1976;33(5):485–490.PubMedCrossRefGoogle Scholar
  27. 27.
    Bossenmeyer-Pourie C, Koziel V, Daval J. CPP32/CASPASE-3-like proteases in hypoxiainduced apoptosis in developing brain neurons. Brain Res Mol Brain Res 1999;71:225–237.PubMedCrossRefGoogle Scholar
  28. 28.
    Banasiak KJ, Cronin T, Haddad GG. bcl-2 prolongs neuronal survival during hypoxia-induced apoptosis. Brain Res Mol Brain Res 1999;72: 214–225.PubMedCrossRefGoogle Scholar
  29. 29.
    Chen EY, Fujinaga M, Giaccia AJ. Hypoxic microenvironment within an embryo induces apoptosis and is essential for proper morphological development. Teratology 1999;60:215–225.PubMedCrossRefGoogle Scholar
  30. 30.
    Suzuki H, Tomida A, Tsuruo T. A novel mutant from apoptosis-resistant colon cancer HT- 29 cells showing hyper-apoptotic response to hypoxia, low glucose and cisplatin. Jpn J Cancer Res 1998;89:1169–1178.PubMedCrossRefGoogle Scholar
  31. 31.
    Gee MS, Koch CJ, Evans SM, et al. Hypoxiamediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Res 1999;59:4882–4889.PubMedGoogle Scholar
  32. 32.
    Khan S, Cleveland RP, Koch CJ, et al. Hypoxia induces renal tubular epithelial cell apoptosis in chronic renal disease. Lab Invest 1999;79: 1089–1099.PubMedGoogle Scholar
  33. 33.
    Stempien-Otero A, Karsan A, Cornejo CJ, et al. Mechanisms of hypoxia-induced endothelial cell death. Role of p53 in apoptosis. Biol Chem 1999;274:8039–8045.CrossRefGoogle Scholar
  34. 34.
    Blankenberg F, Narula J, Strauss HW. In vivo detection of apoptotic cell death: a necessary measurement for evaluating therapy for myocarditis, ischemia, and heart failure. J Nucl Cardiol 1999;6:531–539.PubMedCrossRefGoogle Scholar
  35. 35.
    Czarnota GJ, Kolios MC, Abraham J, et al. Ultrasound imaging of apoptosis: high-resolution noninvasive monitoring of programmed cell death in vitro, in situ and in vivo. Br J Cancer 1999; 81:520–527.PubMedCrossRefGoogle Scholar
  36. 36.
    Zucker RM, Hunter ES III, Rogers JM. Apoptosis and morphology in mouse embryos by confocal laser scanning microscopy. Methods 1999; 18:473–480.PubMedCrossRefGoogle Scholar
  37. 37.
    Mizukami S, Kikuchi K, Higuchi T, et al. Imaging of caspase-3 activation in HeLa cells stimulated with etoposide using a novel fluorescent probe. FEBS Lett 1999;453:356–360.PubMedCrossRefGoogle Scholar
  38. 38.
    Blankenberg FG, Katsikis PD, Tait JF, et al. Imaging of apoptosis (programmed cell death) with 99mTc-annexin. J Nucl Med 1999;40:184–191.PubMedGoogle Scholar
  39. 39.
    Tait JF, Smith C. Site-specific mutagenesis of annexin V: role of residues from Arg-200 to Lys207 in phospholipid binding. Arch Biochem Biophys 1991;288:141–144.PubMedCrossRefGoogle Scholar
  40. 40.
    Vriens PW, Blankenberg FG, Stoot JH, et al. The use of technetium 99mTc annexin V for in vivo imaging of apoptosis during cardiac allograft rejection. J Thorac Cardiovasc Surg 1998;116: 844–853.PubMedCrossRefGoogle Scholar
  41. 41.
    Davison A, Jones AG, Orvig C, Sohn M. A new class of oxotechnetium(+5) chelate complexes containing a TcON2S2 Core. Inorg Chem 1980;20:1629–1632.CrossRefGoogle Scholar
  42. 42.
    Verbruggen AM, Nosco DL, Van Nerom CG, et al. 99mTc-L,L-Ethylenedicysteine: a renal imaging agent. Labelling and evaluation in animals. J Nucl Med 1992;33:551–557.PubMedGoogle Scholar
  43. 43.
    Van Nerom CG, Bormans GM, De Roo MJ, et al. First experience in healthy volunteers with 99mTc-L,L-ethylenedicysteine, a new renal imaging agent. Eur J Nucl Med 1993;20:738–746.PubMedCrossRefGoogle Scholar
  44. 44.
    Surma MJ, Wiewiora J, Liniecki J. Usefulness of 99mTc-N,N′-ethylene-1-dicysteine complex for dynamic kidney investigations. Nucl Med Commun 1994;15:628–635.PubMedCrossRefGoogle Scholar
  45. 45.
    Verbruggen A, Nosco D, Van Nerom C, et al. Evaluation of 99mTc-L,L-ethylenedicysteine as a potential alternate to 99mTc-MAG3. Eur J Nucl Med 1990;16:429.Google Scholar
  46. 46.
    Van Nerom C, Bormans G, Bauwens J, et al. Comparative evaluation of 99mTc-L,L-ethylenedicysteine and 99mTc-MAG3 in volunteers. Eur J Nucl Med 1990;16:417.Google Scholar
  47. 47.
    Jamar F, Stoffel M, Van Nerom C, et al. Clinical evaluation of 99mTc-L,L-ethylenedicysteine, a new renal tracer, in transplanted patients. J Nucl Med 1993;34:129P.Google Scholar
  48. 48.
    Jamar F, Van Nerom C, Verbruggen A, et al. Clearance of the new tubular agent 99mTc-L,L-ethylenedicysteine: estimation by a simplified method. J Nucl Med 1993;34:129P.Google Scholar
  49. 49.
    Ratner S, Clarke HT. The action of formaldehyde upon cysteine. J Am Chem Soc 1937;59: 200–206.CrossRefGoogle Scholar
  50. 50.
    Blondeau P, Berse C, Gravel D. Dimerization of an intermediate during the sodium in liquid ammonia reduction of L-thiazolidine-4-car- boxylic acid. Can J Chem 1967;45:49–52.CrossRefGoogle Scholar
  51. 51.
    Hay MP, Wilson WR, Moselen JW, et al. Hypoxia-selected antitumor agents. Bis(nitro-imidazolyl)alkanecarboxamides: a new class of hypoxia-selected cytotoxins and hypoxic cell radiosensitizers. J Med Chem 1994;37:381–391.PubMedCrossRefGoogle Scholar
  52. 52.
    Yang DJ, Ilgan S, Higuchi T, et al. Noninvasive assessment of tumor hypoxia with 99mTc-labeled metronidazole. Pharm Res 1999;16:743–750.PubMedCrossRefGoogle Scholar
  53. 53.
    Meyn RE, Milas L, Stephens LC. Apoptosis in tumor biology and therapy. Adv Exp Med Biol 1997;400B:657–667.Google Scholar
  54. 54.
    Meyn RE, Stephens LC, Milas L. Programmed cell death and radioresistance. Cancer Metastas Rev 1996;15(1):119–131.CrossRefGoogle Scholar
  55. 55.
    Meyn RE, Stephens LC, Hunter NR, Milas L. Apoptosis in murine tumors treated with chemotherapy agents. Anticancer Drugs 1995;6: 443–450.PubMedCrossRefGoogle Scholar
  56. 56.
    Meyn RE, Stephens LC, Hunter NR, Milas L. Induction of apoptosis in murine tumors by cyclophosphamide. Cancer Chemother Pharmacol 1994;33:410–414.PubMedCrossRefGoogle Scholar
  57. 57.
    Meyn RE, Stephens LC, Ang KK, et al. Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies. Int J Radiat Biol 1993;64:583–591.PubMedCrossRefGoogle Scholar
  58. 58.
    Stephens LC, Hunter NR, Ang KK, et al. Development of apoptosis in irradiated murine tumors as a function of time and dose. Radiat Res 1993;135:75–80.PubMedCrossRefGoogle Scholar
  59. 59.
    Stephens LC, Ang KK, Schultheiss TE, et al. Apoptosis in irradiated murine tumors. Radiat Res 1991;127:308–316.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • David J. Yang
  • E. Edmund Kim

There are no affiliations available

Personalised recommendations